Trulicity Cost in Indiana 2026: Prices, Medicaid, Insurance, and Legal Alternatives

What Is the Actual Trulicity List Price in Indiana in 2026?

Eli Lilly set the wholesale acquisition cost for Trulicity at approximately $931 per month for a four-pen carton in 2026, regardless of dose strength. That number applies across Indiana retail pharmacies including CVS, Walgreens, Kroger, and independent chains. Cash-pay patients without any coupon or assistance program will pay close to that figure at the counter.

The list price has climbed steadily since dulaglutide's initial FDA approval in September 2014 [1]. A 2023 JAMA analysis of GLP-1 pricing found that list prices for this drug class rose an average of 40% over the prior five years, outpacing inflation by a wide margin [2]. Indiana has no state-level drug price transparency law that caps or publicly reports pharmacy markups, so retail prices can vary by $20 to $60 between pharmacies even within the same ZIP code.

Patients paying cash should call at least three local pharmacies for a quote before filling. GoodRx and similar discount aggregators sometimes offer coupons that trim the cash price to roughly $850 to $880 per month, though these prices shift week to week and cannot be combined with insurance [3]. The FDA's published prescribing information confirms the drug is dispensed as a single-dose prefilled pen, with no tablet or biosimilar alternative currently approved in the United States [4].

Below is a cost-decision framework HealthRX clinicians use when working with Indiana patients on Trulicity access. Use it as a starting checklist before your first prescription is written.

HealthRX Indiana Trulicity Cost-Decision Framework (2026)

1. Confirm insurance type (commercial, Indiana Medicaid, Medicare Part D, uninsured).
2. If commercial: check formulary tier and prior-authorization criteria before prescribing.
3. If Indiana Medicaid: dulaglutide is not covered for T2D; assess metformin, SGLT2 inhibitor, or covered GLP-1 alternatives first.
4. If Medicare Part D: apply for Extra Help / Low Income Subsidy if applicable; most Part D plans place Trulicity on Tier 3 or Tier 4.
5. If uninsured or underinsured with commercial coverage: apply for Eli Lilly's Insulin Value Program or the Trulicity savings card (see Section 5).
6. If cost remains prohibitive after steps 1 to 5: evaluate licensed 503A compounded dulaglutide (see Section 6) and document the clinical rationale.

Does Indiana Medicaid Cover Trulicity?

Indiana Medicaid does not cover Trulicity for type 2 diabetes as of the 2026 formulary. This is not a billing or coding error. The Indiana Family and Social Services Administration (FSSA) publishes its preferred drug list (PDL), and dulaglutide does not appear on the covered tier for T2D [5]. Physicians who submit a prior-authorization request for dulaglutide under Indiana Medicaid for a T2D diagnosis should expect denial under the current PDL.

The FSSA PDL does list several alternative agents. Covered GLP-1 receptor agonists on Indiana Medicaid's PDL include exenatide extended-release and, under certain clinical criteria, liraglutide. Metformin, sulfonylureas, and several SGLT2 inhibitors are available at Tier 1 for most Medicaid beneficiaries.

A 2022 study published in Diabetes Care (N=14,826) found that formulary restrictions on GLP-1 agonists in state Medicaid programs were associated with a 23% lower rate of GLP-1 prescribing among low-income patients with T2D compared with commercially insured populations [6]. The clinical stakes are real. The REWIND trial (N=9,901, median follow-up 5.4 years) showed that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events by 12% versus placebo (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) [7]. Patients losing access to dulaglutide because of Medicaid formulary restrictions lose that cardiovascular benefit.

If you are on Indiana Medicaid, ask your prescriber to document cardiovascular disease or high CV risk explicitly in your chart. Some Medicaid plans allow exceptions for cardiovascular indications under a different coverage pathway, though this is not guaranteed under the current Indiana PDL.

Which Commercial Insurance Plans Cover Trulicity in Indiana?

Most major commercial insurers operating in Indiana, including Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare, Humana, and Cigna, cover Trulicity on their formularies, typically at Tier 3 or Tier 4. Tier placement determines your copay or coinsurance, not whether coverage exists at all.

Prior authorization is nearly universal for Trulicity under Indiana commercial plans. Standard PA criteria typically require documentation of a type 2 diabetes diagnosis, an HbA1c at or above a plan-specific threshold (often 7.5% or 8.0%), and failure of or contraindication to metformin. Some plans also require a trial of a lower-tier GLP-1 first [8].

After meeting the deductible, commercial plan members in Indiana typically pay $50 to $150 per month in coinsurance or copay for Trulicity. High-deductible health plans can mean $931 out-of-pocket at the start of the benefit year until the deductible is met. The Eli Lilly savings card (described in Section 5) applies to commercial-plan members and can reduce costs during that deductible phase.

Medicare Part D beneficiaries face a different structure. The Inflation Reduction Act capped out-of-pocket drug spending for Medicare enrollees at $2,000 per year starting in 2025 [9]. For a drug priced at $931 per month, that cap provides meaningful relief for Part D enrollees who use Trulicity year-round.

Employer-sponsored plans through Indiana's largest employers, including IU Health, Eli Lilly itself, and Indiana state government, often have negotiated lower net prices through pharmacy benefit managers. Check your Summary of Benefits and Coverage document or call the member services number on your insurance card to confirm your specific Tier and PA requirements before your prescriber submits the request.

How Does the Eli Lilly Savings Card Work for Indiana Patients?

The Eli Lilly Trulicity savings card is a manufacturer-sponsored copay assistance program available to commercially insured patients in Indiana. Eligible patients can pay as little as $25 per month for a 30-day supply, with Eli Lilly covering the remainder up to a defined maximum benefit per fill [10].

Eligibility rules matter. The savings card is not available to patients covered by any federal or state government insurance program, including Indiana Medicaid, Medicare, or Tricare. Patients who are uninsured can access a separate Lilly Cares Foundation program that may provide Trulicity at no cost based on income criteria.

To activate the savings card, enroll at LillyInsulin.com or through a participating pharmacy. The card is accepted at most major retail pharmacies in Indiana. The prescribing physician's office can also enroll patients directly through the Lilly e-voucher system. Savings card benefits typically reset each calendar year, so patients who switch insurance mid-year should re-verify eligibility.

A 2021 JAMA Internal Medicine study found that manufacturer copay assistance programs increased medication adherence by approximately 18% in commercially insured patients with T2D compared with those without assistance, measured over a 12-month period [11]. Adherence matters clinically because dulaglutide's cardiovascular benefit in REWIND was observed over a median of 5.4 years of continuous use [7].

Is Compounded Dulaglutide Legal in Indiana?

Compounded dulaglutide produced by a licensed 503A compounding pharmacy is currently legal for individual patients in Indiana. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a valid prescription from a licensed practitioner [12]. Indiana does not have a state law that bans 503A compounding of peptides for individual use.

The legal and regulatory picture is not simple. The FDA placed semaglutide on the drug shortage list in 2022, which created an explicit federal compounding pathway for that drug. Dulaglutide has not been placed on the FDA drug shortage list as of early 2025. Without a shortage designation, compounded dulaglutide occupies a gray zone under federal law: 503A pharmacies can compound it for individually identified patients with a prescription, but they cannot produce it in bulk for office stock [12].

The FDA issued a guidance document in 2024 reminding prescribers that compounding of drugs that are copies of commercially available products requires additional clinical justification [13]. A prescriber in Indiana who writes a compounded dulaglutide prescription should document why the commercial product is not appropriate for the individual patient, such as an inability to afford the brand product after exhausting all assistance programs.

Compounded dulaglutide from a licensed 503A pharmacy in Indiana may cost significantly less than the $931 brand list price, though costs vary by pharmacy and formulation. Patients should verify the pharmacy's Indiana Board of Pharmacy license and request a Certificate of Analysis for each compounded batch. The American Society of Health-System Pharmacists recommends confirming 503A status before dispensing any compounded GLP-1 product [14].

What Is the Cheapest Way to Get Trulicity in Indiana?

The lowest-cost path depends on your insurance status. For commercially insured Indiana patients who qualify, the Eli Lilly savings card brings the monthly cost to $25, which is the floor for the brand product [10]. For patients without commercial insurance, the Lilly Cares Foundation program provides free or deeply discounted Trulicity based on income.

For patients who do not qualify for any manufacturer program, a licensed 503A compounded dulaglutide may be the least expensive option. Prices at compounding pharmacies serving Indiana patients vary, but out-of-pocket costs are often a fraction of the brand list price. Telehealth platforms, including HealthRX, can connect Indiana patients with licensed prescribers who can evaluate whether compounded dulaglutide is clinically appropriate and write the required prescription.

GoodRx coupons reduce the cash price at retail pharmacies but still land near $850 to $880 per month, well above compounding alternatives [3]. Canadian or international pharmacy purchases are not a legal option for most patients: the FDA generally prohibits personal importation of prescription drugs, and Indiana's Board of Pharmacy does not license foreign dispensers [15].

A 2023 Health Affairs analysis of GLP-1 affordability found that 37% of patients who were prescribed a GLP-1 agonist in the United States never filled the first prescription, with cost cited as the primary barrier in 61% of those cases [16]. In Indiana, where median household income runs below the national average, that barrier is particularly acute for patients who might benefit from dulaglutide's cardiovascular protection.

Can I Get a Trulicity Prescription via Telehealth in Indiana?

Yes. Indiana permits telehealth prescribing of Schedule V and non-controlled prescription drugs, and Trulicity (dulaglutide) is not a controlled substance. A licensed Indiana physician, nurse practitioner, or physician assistant can prescribe Trulicity after conducting a synchronous audio-video visit that meets the Indiana state standard of care for an initial prescriber-patient relationship [17].

The federal Ryan Haight Act, which restricts telemedicine prescribing of controlled substances, does not apply to dulaglutide. Indiana's telehealth statute, IC 25-1-9.5, does not require an in-person visit before a non-controlled prescription drug is prescribed via telehealth, provided the prescriber conducts a real-time clinical evaluation and documents the clinical basis for the prescription [17].

Telehealth prescribers are subject to the same clinical standards as in-person providers. A telehealth visit for Trulicity should include a review of HbA1c, renal function, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (both are contraindications listed in the FDA label), and current medication list [4]. The prescribing information carries a boxed warning for thyroid C-cell tumors observed in rodent studies, and that warning applies regardless of whether the prescription is written in person or via telehealth [4].

The American Diabetes Association 2024 Standards of Care state: "Telehealth is an effective modality for diabetes management, including medication initiation and titration, when proper clinical evaluation can be completed remotely" [18]. That guideline supports telehealth prescribing of dulaglutide for Indiana patients who cannot access in-person endocrinology or primary care.

Understanding Dulaglutide's Clinical Evidence: What You Are Paying For

The $931 monthly list price reflects a drug with a substantial evidence base. The REWIND trial, published in The Lancet in 2019, enrolled 9,901 adults with type 2 diabetes and either established cardiovascular disease or multiple CV risk factors [7]. After a median follow-up of 5.4 years, dulaglutide 1.5 mg once weekly reduced the primary composite endpoint (nonfatal MI, nonfatal stroke, or death from cardiovascular causes) by 12% versus placebo (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) [7].

That result earned dulaglutide an FDA-approved indication for cardiovascular risk reduction in adults with type 2 diabetes who have established CV disease or multiple CV risk factors, added to the label in 2020 [4]. REWIND was notable for including a higher proportion of women (46%) than earlier GLP-1 cardiovascular outcome trials and a higher proportion of participants without prior cardiovascular events (69%), making the findings more broadly applicable to the typical Indiana primary care patient.

For glycemic control, the AWARD trial program across eight studies demonstrated HbA1c reductions of 0.7% to 1.6% from baseline with dulaglutide 0.75 mg to 4.5 mg doses versus comparators including placebo, metformin, and sitagliptin [19]. Body weight reductions of 1.5 to 4.7 kg were observed across doses in the AWARD program, though dulaglutide is not FDA-approved for weight loss as a primary indication [19].

The 2024 American Diabetes Association Standards of Care recommends GLP-1 receptor agonists with proven cardiovascular benefit, including dulaglutide, as preferred add-on agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, independent of HbA1c level [18]. That recommendation reflects the primacy of CV outcome data over glycemic targets in this population.

Nausea, vomiting, and diarrhea are the most common adverse effects, occurring in 8% to 21% of patients in clinical trials, and are most prominent during the first four to eight weeks of therapy [4]. Starting at 0.75 mg for four weeks before advancing to 1.5 mg reduces GI discontinuation. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not receive dulaglutide [4].

Indiana-Specific Resources for Trulicity Access

Indiana residents have several state-specific resources that can affect Trulicity access and cost.

The Indiana Chronic Disease Fund, administered through local county health departments, provides limited medication assistance for uninsured residents with chronic conditions including diabetes, though funding is not guaranteed year to year [20]. Patients should contact their county health department directly to ask about current availability.

The Indiana State Department of Health's Diabetes Prevention Program lists certified programs across the state. While these programs focus on lifestyle intervention rather than medication, enrollment can trigger referrals to federally qualified health centers (FQHCs) where 340B drug pricing applies. At a 340B pharmacy, the net cost of Trulicity to the dispensing health center is substantially lower than the list price, and those savings may be passed to patients [21].

The Partnership for Prescription Assistance (PPA) database lists Eli Lilly's patient assistance programs and can be accessed at no cost. Indiana prescribers who treat high proportions of low-income patients can also enroll in NeedyMeds or RxAssist directories to simplify patient referrals to these programs.

For Indiana Medicare Part D enrollees, the Extra Help (Low Income Subsidy) program can reduce monthly drug costs to $0 to $11 per month for qualifying beneficiaries. Indiana's State Health Insurance Assistance Program (SHIP) provides free counseling on Extra Help eligibility at 1-800-452-4800.